Payment overview · 2025
General Payments
$1,131.73
44 reported records · 15 companies
Healthcare provider profile · identity verified
Eva Marie Wolf, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GREENVILLE, SC · NPI 1437578069
Verified facts
What the public records show
CMS Open Payments records show Eva Marie Wolf, M.D. received $1,131.73 in general payments during 2025 across 44 reported records.
Lilly USA, LLC accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $296.10 | 26.2% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $246.09 | 21.7% | 12 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $162.20 | 14.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $67.46 | 6.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.27 | 5.0% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $49.48 | 4.4% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.24 | 3.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.75 | 3.6% | 2 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $39.12 | 3.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.31 | 3.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.74 | 2.3% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $25.08 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.41 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.28 | 1.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.20 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,131.73 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $215.44 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $179.36 | 8 | 2025 |
Source payment records
|
|||||
| GORE SYNECOR Preperitoneal Biomaterial Normalized: gore synecor preperitoneal biomaterial |
Device | W. L. Gore & Associates, Inc. | $162.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $102.52 | 7 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $67.46 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $56.27 | 4 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $49.48 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.61 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.61 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $44.03 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $43.24 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.75 | 2 | 2025 |
Source payment records
|
|||||
| Phasix Mesh Normalized: phasix mesh |
Device | Davol Inc. | $39.12 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $11.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 85 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 468 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 337 | 109 |
| Losartan Potassium | Losartan Potassium | 331 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 301 | 89 |
| Lisinopril | Lisinopril | 251 | 82 |
| Omeprazole | Omeprazole | 241 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 66 |
| Trazodone Hcl | Trazodone Hcl | 189 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 179 | 99 |
| Metformin Hcl Er | Metformin Hcl | 176 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 169 | 81 |
| Montelukast Sodium | Montelukast Sodium | 148 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 49 |
| Gabapentin | Gabapentin | 135 | 53 |
| Famotidine | Famotidine | 133 | 58 |
| Ozempic | Semaglutide | 127 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 47 |
| Spironolactone | Spironolactone | 126 | 42 |
| Alendronate Sodium | Alendronate Sodium | 124 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 123 | 51 |
| Bupropion Xl | Bupropion Hcl | 115 | 40 |
| Metformin Hcl | Metformin Hcl | 115 | 35 |
| Furosemide | Furosemide | 114 | 56 |
| Methylprednisolone | Methylprednisolone | 100 | 83 |
| Sertraline Hcl | Sertraline Hcl | 98 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 46 |
| Prednisone | Prednisone | 89 | 60 |
| Eliquis | Apixaban | 85 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 26 |
| Mirtazapine | Mirtazapine | 75 | 27 |
| Carvedilol | Carvedilol | 65 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 22 |
| Celecoxib | Celecoxib | 61 | 28 |
| Fluconazole | Fluconazole | 60 | 51 |
| Meloxicam | Meloxicam | 60 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 55 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 15 |
| Alprazolam | Alprazolam | 52 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 33 |
| Mounjaro | Tirzepatide | 50 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 12 |
| Pregabalin | Pregabalin | 47 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 19 |
| Jardiance | Empagliflozin | 46 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 43 |
| Atenolol | Atenolol | 45 | 17 |
| Allopurinol | Allopurinol | 44 | 13 |
| Potassium Chloride | Potassium Chloride | 44 | 17 |
| Ezetimibe | Ezetimibe | 43 | 15 |
| Ondansetron Odt | Ondansetron | 42 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 18 |
| Linzess | Linaclotide | 41 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 17 |
| Synthroid | Levothyroxine Sodium | 36 | 11 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 14 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Nystatin | Nystatin | 28 | 15 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 26 | 26 |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Naproxen | Naproxen | 23 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Droxidopa | Droxidopa | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,131.73 · 44 records | Lilly USA, LLC | Auvelity, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GORE SYNECOR Preperitoneal Biomaterial, INSPIRE, JARDIANCE, KISUNLA, LAGEVRIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, Phasix Mesh, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, Tresiba, UBRELVY, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error